PURETECH HEALTH PLC
Listed on the London Stock Exchange and Nasdaq, the business is a biotherapeutics group that develops medicines for serious diseases through its own internal pipeline and a hub-and-spoke model of founded subsidiary entities.
Get an alert when PURETECH HEALTH PLC files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£252M
-10% vs 2024
Net assets
£306M
-25.1% lowest in 3 filed years
Employees
62
-22.5% lowest in 4 filed years
Profit before tax
-£110M
-496.2% lowest in 4 filed years
Net assets
4-year trend · vs Health Care median
Accounts
4-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|---|
| Turnover | £11,691,870 | £2,580,000 | £4,315,000 | £4,659,000 | +8% | |
| Operating profit | -£148,081,300 | -£146,199,000 | -£136,095,000 | -£98,527,000 | +27.6% | |
| Profit before tax | -£41,712,083 | -£30,525,000 | £27,782,000 | -£110,084,000 | -496.2% | |
| Net profit | — | — | — | -£110,084,000 | — | |
| Cash | £112,191,945 | £143,046,115 | £280,641,000 | £252,470,000 | -10% | |
| Total assets less current liabilities | — | £481,062,285 | £565,641,000 | £501,915,000 | -11.3% | |
| Net assets | — | — | £407,933,000 | £305,676,000 | -25.1% | |
| Equity | — | £343,039,377 | £407,933,000 | £305,676,000 | -25.1% | |
| Average employees | 144 | 96 | 80 | 62 | -22.5% | |
| Wages | £31,254,679 | £37,084,000 | £29,032,000 | £22,475,000 | -22.6% | |
| Directors' remuneration | — | £2,561,083 | £8,051,169 | £1,979,646 | -75.4% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|
| Return on capital employed | — | -30.4% | -24.1% | -19.6% | |
| Gearing (liabilities / total assets) | — | — | 32.3% | 42.8% | |
| Current ratio | — | 6.76x | 10.44x | 9.30x | |
| Interest cover | -1.38x | -42.70x | -76.85x | -52.52x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Consolidated group
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“As of December 31, 2025, the directors had a reasonable expectation that the Group had adequate financial resources to continue in operational existence for a period of at least twelve months from the date the financial statements are issued.”
Group structure
- PURETECH HEALTH PLC · parent
- PureTech LYT 100, Inc. 100%
- PureTech LLC 100%
- PureTech Health plc 100%
- PureTech Securities II Corporation 100%
- PureTech Management, Inc. 100%
- Gallop Oncology, Inc. 100%
- Enlight Holdings, LLC 86%
- Ensof Holdings, LLC 86%
- Akil Immune Labs, Inc. 100%
- Appeering, Inc. 100%
- Commense Inc. 99.1%
- Enliht Biosystems, LLC 86%
- Follca, LLC 57.7%
- Libira Biosciences, Inc. 100%
- Mandara Sciences, LLC 98.3%
- Tal Medical, LLC 100%
- Seaport Therapeutics, Inc. 42.1%
- Karuna Therapeutics, Inc. 42.1%
- Entraga, Inc. 77.3%
- Gelesis, Inc. 85.4%
- Vedanta Biosciences, Inc. 51%
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
7 active · 11 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| SHERWOOD, Charles | Secretary | 2024-04-23 | — | — |
| BARBER-LUI, Sharon | Director | 2022-03-24 | Jun 1973 | American |
| HOLCOMB, Michele Ann Mc Mahon | Director | 2024-09-23 | Apr 1968 | American |
| LA MATTINA, John Lawrence, Dr. | Director | 2015-06-05 | Jan 1950 | American |
| LANGER, Robert Samuel, Dr | Director | 2015-06-05 | Aug 1948 | American |
| LYNE, Robert William Henry | Director | 2025-12-18 | Sep 1983 | British |
| MAZUMDAR-SHAW, Kiran | Director | 2020-09-30 | Mar 1953 | Indian |
Show 11 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| CHOWRIRA, Bharatt | Secretary | 2021-04-14 | 2024-04-23 |
| MUNIZ, Stephen | Secretary | 2015-05-08 | 2021-04-14 |
| CHOWRIRA, Bharatt | Director | 2021-02-01 | 2025-07-16 |
| ITO, Joichi | Director | 2015-06-05 | 2019-09-07 |
| KUCHERLAPATI, Raju, Dr | Director | 2015-06-05 | 2025-07-08 |
| MUNIZ, Stephen | Director | 2015-05-08 | 2021-05-17 |
| SCARDINO, Marjorie Morris, Dame | Director | 2015-06-05 | 2022-12-31 |
| SHAPIRO, Bennett Michael, Dr. | Director | 2015-06-05 | 2020-06-11 |
| VIEHBACHER, Christopher | Director | 2015-06-05 | 2023-06-13 |
| ZOHAR, Daphne | Director | 2015-05-08 | 2024-04-08 |
| INTERTRUST TRUSTEES (UK) LIMITED | Corporate Director | 2015-05-08 | 2015-05-08 |
Ownership
Persons with significant control
Filing timeline
Last 20 of 221 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-06-21 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-06-21 | AA | accounts | Accounts with accounts type group | |
| 2026-06-18 | CH01 | officers | Change person director company with change date | |
| 2026-05-08 | CH01 | officers | Change person director company with change date | |
| 2026-05-08 | CH01 | officers | Change person director company with change date | |
| 2026-05-07 | CH01 | officers | Change person director company with change date | |
| 2026-02-02 | TM01 | officers | Termination director company with name termination date | |
| 2026-02-02 | AP01 | officers | Appoint person director company with name date | |
| 2026-02-02 | TM01 | officers | Termination director company with name termination date | |
| 2025-05-19 | AA | accounts | Accounts with accounts type group | |
| 2025-05-14 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-10-30 | SH06 | capital | Capital cancellation shares | |
| 2024-10-30 | SH04 | capital | Capital sale or transfer treasury shares with date currency capital figure | |
| 2024-10-30 | SH04 | capital | Capital sale or transfer treasury shares with date currency capital figure | |
| 2024-10-30 | SH03 | capital | Capital return purchase own shares | |
| 2024-09-27 | AP01 | officers | Appoint person director company with name date | |
| 2024-09-13 | SH03 | capital | Capital return purchase own shares treasury capital date | |
| 2024-09-13 | SH03 | capital | Capital return purchase own shares treasury capital date | |
| 2024-09-13 | SH03 | capital | Capital return purchase own shares treasury capital date | |
| 2024-09-13 | SH03 | capital | Capital return purchase own shares treasury capital date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 9
- Capital events
- 8
- Officers appointed
- 1
- Officers resigned
- 2
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.